-
-
Humanized model of the immune system
-
iHuPBMC-T
-
iHuPBMC-NK
-
iHuPBMC-B
-
PBMC-LT
-
CD34+ HSC
-
Winn model
-
iHuPBMC-MHC/KO
-
iHuPBMC-OncVax
-
PBMC mixed inoculation model
more -
-
In vivo tumor experimental platform
-
CDX
-
iHuPDX
-
Non-GLP Toxicology
-
PK/PD
-
Brain in situ model
-
Other in situ models
-
Hematologic tumor model system inoculation
-
Creation of high interstitial tumor models
more -
-
In vitro killing experiment platform
-
Immune co-culture killing model
-
CDC
-
In vitro killing experiment platform
-
IC50
-
PDC High-Throughput In Vitro Pharmacodynamics
-
3D organoids
-
ADCC
-
T cell-mediated killing experiment
more -
-
Mouse-derived immune system model
more -
Tumor vaccine
more -
Cell therapy
more -
In vitro testing platform
more -
Non-GLP Toxicology Platform
more -
Non-tumor model and drug efficacy evaluation platform
-
Systematic Vaccination Model
-
Non-tumor model and drug efficacy evaluation platform
-
Skin injury model
-
Stroke model
-
Liver fibrosis model
-
Diabetes model
-
Gouty Arthritis (GA) Model
-
Pulmonary fibrosis model
-
Systemic lupus erythematosus (SLE) model
-
Inflammatory Bowel Disease (IBD) model
-
Rheumatoid Arthritis (RA) Model
more -
-
-
-
PDX model
-
PDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
CDX model
-
CDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
Homogeneous Model
-
Homogeneous Model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Breast cancer
-
Stomach cancer
-
Liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Pancreatic cancer
-
Kidney cancer
-
Bladder cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer
-
Ovarian cancer
-
Esophageal cancer
-
Skin cancer
-
sarcoma
-
Nervous System Cancer
-
Embryonal carcinoma
-
Lymphoma
-
Leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other
-
Colorectal cancer
more -
-
News Center
——
InnoModels Biotechnology: What are the advantages of the CDX modeling platform?
Author:
InnoModels
Release time:
2024-05-23
In the vast field of biomedical research, cancer research has always been an important challenge for scientists. In order to better understand the biology of cancer and find effective treatments, the InnoModels Bio CDX modeling platform has emerged to provide strong support for cancer research and drug development with its unique features and advantages.
The InnoModels Bio CDX modeling platform is a cancer tissue-based xenograft technology, which establishes a cancer model by transplanting a patient's cancer tissue into an animal, such as a mouse, to form a human-derived xenograft tumor. The emergence of this technology provides scientists with a research tool that is closer to clinical reality, enabling them to gain a deeper understanding of cancer onset, progression, and the mechanism of drug action on tumors.
The platform has a large library of tumor cell lines covering a wide range of cancer types and subtypes. This enables researchers to select the most suitable cell lines for their studies, ensuring the accuracy and reliability of experimental results. Whether it is for in-depth research on a specific type of cancer or extensive drug screening, the InnoModels Bio CDX modeling platform provides a wealth of experimental resources and options.
In addition to a large library of tumor cell lines, the InnoModels Biotechnology CDX model platform is also highly portable. By transplanting cancer tissues from patients into mice, the heterogeneity of the original cancer tissues can be maintained, enabling researchers to gain a more comprehensive understanding of the complex characteristics of tumors. At the same time, the high portability of transplanted tumors in mice also makes drug development much more efficient, allowing researchers to evaluate the effects of different drugs on tumors more quickly, thus accelerating the process of developing new drugs.

It is worth mentioning that the CDX modeling platform of InnoModels Biotechnology also has an excellent experimental design and management team. This team consists of experienced experts who have more than ten years of experience in the field of CDX modeling. They understand the complexity of CDX modeling and are able to provide valuable insights and guidance on experiment design and implementation. Whether it is from the development of experimental protocols, the execution of experimental operations, or the analysis and interpretation of data, InnoModels Biotechnology can provide professional support and assistance.
In addition, the InnoModels Biotechnology CDX modeling platform is flexible and scalable. Researchers can choose different transplantation methods (e.g., subcutaneous, in situ inoculation, etc.) and experimental conditions according to their needs to meet specific research purposes. Meanwhile, the platform can also be combined with other advanced technologies, such as in vivo imaging and gene editing, to further expand the scope and depth of experiments.
Overall, with its unique technological features and advantages, the InnoModels Biotechnology CDX modeling platform has revolutionized cancer research and drug development. It not only provides a wealth of experimental resources and options, but also features high portability, an excellent experimental design and management team, as well as flexibility and scalability. It is believed that in the near future, the InnoModels Biotechnology CDX modeling platform will continue to lead a new era of cancer research and drug development, and make greater contributions to mankind's victory over the persistent disease of cancer.
InnoModels Biotechnology (Beijing) Co., Ltd.
-
TEL: +86 15711355061
-
E-mail: xuyl@imodels.tech
-
Address: Building 14, No. 79 West Shuangying Road, Changping District, Beijing
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.
These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.
These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.
These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.
InnoModels Biotechnology (Beijing) Co., Ltd